Medicaid funding for a Houston hospital's renowned heart transplant program could be cut off in mid-August because it hasn't done enough to correct problems identified after the deaths of two patients, federal officials say.
FDA approves test to detect mutations in 324 genes, two genomic signatures. Second to be approved with proposed coverage under FDA/CMS Parallel Review Program.